Carltonine B derivatives: Synthesis and structure-activity relationship insights for selective butyrylcholinesterase inhibition
Abstract
Butyrylcholinesterase (BChE) is recognized as a promising therapeutic target for the late stages of Alzheimer's disease (AD) due to its role in the hydrolysis of acetylcholine (ACh), while acetylcholinesterase (AChE) activity declines during disease progression. Here, we have reported an efficient chemistry procedure for the naturally occurring Amaryllidaceae alkaloid carltonine B, along with the design and synthesis of 36 novel carltonine-based analogues to determine structure-activity relationship (SAR). Most of the synthesized compounds exhibited potent and selective human BChE ( h BChE) inhibition, with IC 50 values ranging from low micromolar to nanomolar concentrations. The drug-like properties of the molecules were assessed by in silico tools, using the blood-brain barrier (BBB) score algorithm, and subsequently validated by in vitro permeability assessment via parallel artificial membrane permeability assay (PAMPA). The derivatives exhibited potent h BChE inhibition in the low micromolar to submicromolar range, while their cytotoxicity against human neuroblastoma (SH-SY5Y) cells was observed only at higher micromolar concentrations, indicating a favorable safety profile. The synthesized alkaloid carltonine B ( 37 ) and its N -ethyl derivative ( 38 ) emerged as the most potent and selective h BChE inhibitors, with IC 50 values of 0.014 ± 0.002 μM and 0.013 ± 0.001 μM, respectively. Enzyme kinetic studies were conducted to elucidate the inhibition mechanism toward h BChE enzyme. Compound 37 demonstrated competitive inhibition with K i value of 0.055 μM. In contrast, compound 38 showed a noncompetitive inhibition profile, with a K i value of 0.067 μM. Molecular modeling suggested that the superior potency of compounds 37 and 38 arises from their more optimal engagement of the BChE active-site gorge compared to compound 33 . For the additional safety assessment, CYP inhibition assay revealed that compounds 37 and 38 may pose a risk of CYP3A4-mediated drug-drug interactions during chronic administration. • A scalable synthesis of carltonine B and 36 novel analogues was developed. • SAR analysis identified key structural features for selective h BChE inhibition. • Carltonine B derivatives showed micromolar to nanomolar h BChE inhibition with high selectivity. • Lead compounds displayed good BBB permeability and low neuronal cytotoxicity. • Kinetic studies revealed competitive and non-competitive h BChE inhibition modes.
Related
- Design and Synthesis of New Derivatives of Alkaloid Lupinine: Structural Characterization, Acetylcholinesterase Inhibition Evaluation, and Molecular Modeling Study
- Carbazole derivatives as privileged scaffolds for kinase inhibition: advances in design, therapeutic applications and mechanisms
- Synthesis of N-Protected L-DOPA(acetonide) Derivatives
- Chemical Synthesis and Immunological Evaluation of Archaeal Rare Sugar L-TalNAcA and Its Derivatives
- Synthesis of cyclobutane-fused oxazolidine-2-thione derivatives
BibTeX
@article{mamun2026carltonine,
title = {{Carltonine B derivatives: Synthesis and structure-activity relationship insights for selective butyrylcholinesterase inhibition}},
author = {Abdullah Al Mamun and Jan Konecny and Martina Hrabinova and Ales Sorf and Lubica Muckova and Jakub Fibigar and Tomas Kucera and Lenka Pulkrabkova and Daniel Jun and Lukas Prchal and Dawid Panek and Vladimir Finger and Ondrej Soukup and Thomas Cailly and Valérie Collot and Lucie Novakova and Lucie Cahlikova and Jan Korabecny},
journal = {Bioorganic Chemistry},
year = {2026},
month = sep,
doi = {10.1016/j.bioorg.2026.109894},
url = {https://hal.science/hal-05767870v1},
note = {CC BY},
}
RIS
TY - JOUR
TI - Carltonine B derivatives: Synthesis and structure-activity relationship insights for selective butyrylcholinesterase inhibition
AU - Abdullah Al Mamun
AU - Jan Konecny
AU - Martina Hrabinova
AU - Ales Sorf
AU - Lubica Muckova
AU - Jakub Fibigar
AU - Tomas Kucera
AU - Lenka Pulkrabkova
AU - Daniel Jun
AU - Lukas Prchal
AU - Dawid Panek
AU - Vladimir Finger
AU - Ondrej Soukup
AU - Thomas Cailly
AU - Valérie Collot
AU - Lucie Novakova
AU - Lucie Cahlikova
AU - Jan Korabecny
PY - 2026
DA - 2026/09/28
JO - Bioorganic Chemistry
DO - 10.1016/j.bioorg.2026.109894
UR - https://hal.science/hal-05767870v1
AB - Butyrylcholinesterase (BChE) is recognized as a promising therapeutic target for the late stages of Alzheimer's disease (AD) due to its role in the hydrolysis of acetylcholine (ACh), while acetylcholinesterase (AChE) activity declines during disease progression. Here, we have reported an efficient chemistry procedure for the naturally occurring Amaryllidaceae alkaloid carltonine B, along with the design and synthesis of 36 novel carltonine-based analogues to determine structure-activity relationship (SAR). Most of the synthesized compounds exhibited potent and selective human BChE ( h BChE) inhibition, with IC 50 values ranging from low micromolar to nanomolar concentrations. The drug-like properties of the molecules were assessed by in silico tools, using the blood-brain barrier (BBB) score algorithm, and subsequently validated by in vitro permeability assessment via parallel artificial membrane permeability assay (PAMPA). The derivatives exhibited potent h BChE inhibition in the low micromolar to submicromolar range, while their cytotoxicity against human neuroblastoma (SH-SY5Y) cells was observed only at higher micromolar concentrations, indicating a favorable safety profile. The synthesized alkaloid carltonine B ( 37 ) and its N -ethyl derivative ( 38 ) emerged as the most potent and selective h BChE inhibitors, with IC 50 values of 0.014 ± 0.002 μM and 0.013 ± 0.001 μM, respectively. Enzyme kinetic studies were conducted to elucidate the inhibition mechanism toward h BChE enzyme. Compound 37 demonstrated competitive inhibition with K i value of 0.055 μM. In contrast, compound 38 showed a noncompetitive inhibition profile, with a K i value of 0.067 μM. Molecular modeling suggested that the superior potency of compounds 37 and 38 arises from their more optimal engagement of the BChE active-site gorge compared to compound 33 . For the additional safety assessment, CYP inhibition assay revealed that compounds 37 and 38 may pose a risk of CYP3A4-mediated drug-drug interactions during chronic administration. • A scalable synthesis of carltonine B and 36 novel analogues was developed. • SAR analysis identified key structural features for selective h BChE inhibition. • Carltonine B derivatives showed micromolar to nanomolar h BChE inhibition with high selectivity. • Lead compounds displayed good BBB permeability and low neuronal cytotoxicity. • Kinetic studies revealed competitive and non-competitive h BChE inhibition modes.
SN - 0045-2068
SN - 1090-2120
ER -